Lexeo Therapeutics, Inc.
LXEO
$5.05
$0.347.22%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -48.11% | -29.67% | -21.16% | -8.28% | -12.01% |
| Total Depreciation and Amortization | 8.63% | 9.62% | 14.40% | 32.48% | 60.96% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 248.47% | 230.77% | 218.55% | 212.28% | 100.62% |
| Change in Net Operating Assets | 84.14% | 4,265.78% | 2,100.00% | 463.67% | -17.25% |
| Cash from Operations | -36.40% | -7.51% | -4.95% | 6.47% | -9.05% |
| Capital Expenditure | -318.26% | -726.87% | -12.86% | 43.02% | 82.89% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -187,092.00% | 90.15% | 50.00% | 67.32% | 78.17% |
| Cash from Investing | -56,916.36% | -184.92% | 1.65% | 49.15% | 81.69% |
| Total Debt Issued | -- | -100.00% | -- | -- | -- |
| Total Debt Repaid | 3.53% | 6.78% | -10.64% | -60.91% | -160.74% |
| Issuance of Common Stock | -4.80% | 239,686.08% | 386,475.51% | 98,365.10% | 30,111.45% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -7,211.63% | -581.82% | -- | -- | -- |
| Cash from Financing | -14.47% | 5,092.20% | 62,738.96% | 313,178.05% | 54,815.87% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -295.90% | 307.10% | 312.78% | 324.65% | 179.84% |